Skip to Main Content

Chapter 64. Emergency Resuscitation Measures

Which of the following statements is true regarding the use of therapeutic hypothermia in patients surviving sudden cardiac death?

A. There is clear evidence to support the use of rapid cooling (ie, within the first 2 hours of cardiac arrest).

B. The largest randomized trial of therapeutic hypothermia found no benefit of cooling to a goal temperature of 36°C compared to 33°C.

C. Trials have shown a significant increase in bleeding complications in patients undergoing therapeutic hypothermia.

D. Current recommendations are that therapeutic hypothermia should be continued for 48 hours followed by gradual rewarming.

E. All of the above are true.

The correct answer is B

Current recommendations for the initial management of cardiac arrest patients include which of the following?

A. The use of inspiratory impedance threshold devices if available

B. High-quality uninterrupted cardiopulmonary resuscitation (CPR) if the initial responders are uncomfortable with mouth-to-mouth resuscitation

C. After placement of an advanced airway, asynchronous respirations should be provided at a rate of 15 to 20 breaths per minute

D. Interposed abdominal compression CPR (IAC-CPR) should never be used during the initial management of cardiac arrest patients

E. There are clear data to support the use of automated chest compression devices instead of conventional CPR

The correct answer is B

Which of the following causes of sudden cardiac death is the leading cause in the United States?

A. Long QT syndrome

B. Chronic systolic heart failure

C. Coronary artery disease

D. Hypertrophic cardiomyopathy

E. Congenital heart disease

The correct answer is C

Which of the following is no longer currently recommended during advanced cardiac life support?

A. Epinephrine every 3 to 5 minutes

B. Placement of a transvenous pacer for those with asystole

C. Amiodarone (300 mg bolus) to those with refractory ventricular tachycardia or ventricular fibrillation

D. Atropine (1 mg) to patients with pulseless electrical activity or asystole


Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.